ClinicalTrials.gg
RecruitingNCT04132206ScleroBiotiqueUpdated Sep 25, 2025

Longitudinal Characterization of Microbial Signature in Systemic Sclerosis Patients

An observational study in Systemic Sclerosis, sponsored by Hôpital Européen Marseille. Recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-25.

Sponsored by Hôpital Européen Marseille · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Oct 2019; still recruiting 7 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 132 studies in Scleroderma, Systemic with a site in France — 44 open to participants now, 48 under way, 7 of them phase 3. Scleroderma, Systemic · France.

Planned enrollment
38th of 50
60 · median 150
Started
2019
with 3 others
Observational
51 of 132
17 open now
Primary completion
2026-06
later than 11 of 47 live
Registered
63rd of 132
by date

Among the 132 studies in Scleroderma, Systemic with a site in France, this one is the 38th largest by planned enrollment of the 50 observational ones that give a count, is one of 4 that started in 2019, is one of 51 observational ones, reaches primary completion later than 11 of the 47 other live ones, and was the 63rd registered.

Scleroderma, Systemic

614 studies on the registry are indexed under Scleroderma, Systemic; 222 are open to participants now.

Browse Scleroderma, Systemic studies →

Open to participants now

44 of the 132 studies in Scleroderma, Systemic with a site in France are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 147 Scleroderma, Systemic studies recruiting now, 85 (58%) set no upper age limit and 49 (33%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies in Scleroderma, Systemic with a site in France, or all of them as a file.
02

Study summary

Today, the study of gut microbiota has taken a prominent place in several fields of medical research. Numerous experimental data in humans and animals suggest that an imbalance in the composition of the microbiota could contribute to the pathophysiology of systemic autoimmune diseases such as Systemic Sclerosis (SCS). A future exploration of the microbiota, a source of diagnostic and/or prognostic biomarkers, may be very useful for tomorrow's medicine by proposing therapeutic interventions based on the correction of possible imbalances in the intestinal flora. Studies of the human gut microbiota in patients with ScS are limited to low-impact investigations, due to the lack of data on the clinical and biological characterization of the patients studied, and to the absence of longitudinal studies in the same patient. For this reason, we are interested in exploring the intestinal microbiota of ScS patients in a comprehensive and longitudinal way.

Read the detailed description

This is an explorative, prospective, monocentric open-label study qualified as interventional researches at minimal risks and constraints (called in French RIPH, category 2).

This is a study of the gut microbiota and its characteristics in ScS patients, compared to control subjects (without ScS or other chronic diseases), matched on age and sex.

Participants provided two stool samples: one collected the day of inclusion and a second, six months later.

In parallel with the microbiota analysis, a clinical (digestive and extra digestive signs, severity) and biological characterization of the ScS will be carried out by the team of internists. This medical evaluation will be completed by an interview with a dietician to inform about the participant's eating habits, and any changes in the 7 days preceding the stool collection.

Microbial profiles will be obtained from the sequencing data using the specialized tools DADA2 and Kraken.

The search of characteristic signature of ScS will be performed by comparing ScS patients and healthy controls using a discriminant linear analysis (LDA) using the specialized tool LEfSe Main objective is to identify, through longitudinal follow-up, significant differences in the composition of the intestinal microbiota of ScS patients and healthy control subjects (matched on age and sex) in order to define a microbial signature specific to the ScS.

Secondary objectives are to study the stability over time of the identified microbial signatures, and to determine a correlation between the composition of the microbiota obtained in the ScS patient and the severity of his symptoms (diffuse skin disease, pulmonary interstitial disease, digestive disease...)

03

Conditions studied

  • Systemic Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with ScS according to ACR criteria,and healthy volunteers without diagnosis of ScS or any other chronic disease

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For ScS patients:

  1. Patients with ScS according to ACR criteria.
  2. Patients over 18 years old.
  3. Patients who have signed the consent to participate in this study.

For control subjects:

  1. Persons without diagnosis of ScS or any other chronic disease.
  2. Persons over 18 years old.
  3. Persons who have signed the consent to participate in this study

Exclusion criteria

Exclusion Criteria:

  • 1. Persons with severe anemia ( \< 7 g/dL). 2. Persons who cannot read French. 3. For control subjects: Persons with a particular symptom (as an example of digestive disorders), or under long-term treatment related to another pathology.

    4. Persons treated with antibiotics, probiotics, prebiotics or any other treatment that may disrupt the gut microbiota within two months before stool sampling.

    5. Persons referred to the article L1121-5 to 1121-8 of the Public health code, namely :

  • Pregnant, women in labour and breastfeeding mothers.
  • Persons deprived of their liberty by a judicial or administrative decision.
  • Persons undergoing psychiatric follow-up.
  • Minors
  • Persons of full-age who are subject to a legal protection measure or who are unable to express their consent.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • ScS patients

    Patients will provide two stool samples: one collected the day of inclusion and a second, six months later

    Other: stool sampling

  • Healthy subjects

    Healthy subjects will provide one stool sample at inclusion.

    Other: stool sampling

Interventions

  • Otherstool sampling

    Participants will provide two stool samples: one collected the day of inclusion and a second, six months later

06

What researchers measure

Primary outcomes

  1. Differences on gut microbiota composition (bacterial populations) of ScS overtime, at different taxonomic levels (from phyla to species if technique allows) versus healthy controls.

    The patient participation at the study will last 7 months, but healthy volunteers will provide stool sample only once at study entry and won't be followed after that.

    Time frame: 7 months

07

Study locations

1 of 1 sites recruiting
  • Hôpital Européen Marseille
    Marseille, 13003, France
    Recruiting
    • Chloé STAVRIS, MD · Contactc.stavris@hopital-europeen.fr · 06 23 01 64 25
    • Eya TOUMY, PhD student · Contacte.toumi@alphabio.fr · 04 13 42 81 50
    • Chloé STAVRIS, MD · Principal investigator
    • Laurent CHICHE, MD · Sub investigator
    • Philippe HALFON, MD · Sub investigator
    • Caroline CHARPIN, MD · Sub investigator
    • Frédérique RETORNAZ, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2019 (actual). Primary completion is estimated for Jun 2026, 79 months after the start.

Of 59 non-industry observational studies under Scleroderma, Systemic, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 80. This study's planned 79 months is above that.

Counting every sponsor, half of 61 studies reached it within 44 months; a quarter within 17 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2019
First posted
Oct 18, 2019
StartActual
Oct 8, 2019
Primary completionEst.
Jun 3, 2026
CompletionEst.
Jun 3, 2026
Last update
Sep 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04132206
Lead sponsor
Hôpital Européen Marseille
Responsible party
Sponsor
First posted
Oct 18, 2019
Start date
Oct 8, 2019
Primary completion
Jun 3, 2026 (estimated)
Completion
Jun 3, 2026 (estimated)
Last update
Sep 25, 2025

Study contacts

Eya TOUMI, PhD student
Contact
e.toumi@alphabio.fr
04 13 42 81 50
Chloé STAVRIS, MD
principal investigator · Hôpital Européen Marseille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion